) -- I'm trying to incorporate more actual tweets in the Biotech Stock Mailbag.
Earlier this week, the American Society of Clinical Oncology (ASCO) posted the itinerary planner for its annual meeting.
Research abstract titles and presentation times
are now available and searchable.
I fear this year's ASCO meeting might be a tad boring from a Wall Street perspective. ASCO is cyclical, with strong and weak years. The upcoming meeting looks to be the latter. With that said, here are some highlights based on my first, quick look through the abstracts:
This year's plenary session features two presentations on
Avastin, one each in glioblastoma (brain cancer) and cervical cancer.
will also present results from the phase III "Decision" trial of Nexavar in thyroid cancer.
: Updated results from the phase II "Galaxy-1" study of ganetespib in non-small cell lung cancer. Abstract No. CRA8007.
: Detailed results from the positive phase III study of T-Vec in melanoma. Abstract No. LBA9008.
: Updated results from the early, proof-of-concept study of AP26113. Abstract No. 8031
will have several presentation on PI3k inhibitor idealisib. Check out abstract nos. 8519, 7005, 8500 and 8501.
anti PD-1 nivolumab will definitely take a star turn at the ASCO meeting this year. Check out abstract nos. 9011, 9012, CRA9006 and 3002.
Roche also has a PD-L1 antibody, MPDL3280A, in development. Abstract Nos. 4505, 3000 and 8008.
FDA just awarded
anti PD-1 lambrolizumab with breakthrough therapy designation. Check out abstract no. 9009.
: The failed Stimuvax lung cancer phase III trial will be presented. Abstract No. 7500.
: Phase II data from the combination study of selumitinib plus dacarbazine in melanoma. Abstract No. 9004
That's a start. The contents of most of the ASCO research abstracts will be posted online May 15 at 6 pm ET. There will be much more to talk about once we get more than just the titles.
(SRPT - Get Report)
shares are weak due to heightened speculation that FDA will reject the company's request to seek accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The confidence of the "no accelerated approval" crowd has been bolstered by a series of conference calls sponsored by sell-side analysts over the past week. These calls have featured experts expressing doubts about Sarepta's ability to correlate dystrophin production with the benefit observed by patients on the six-minute walk test.